Durham, NC - March 2, 2020 - JSR Life Sciences, LLC announced today that Dirk Lange will take over as president and chief executive officer of KBI Biopharma, Inc., a leading contract development and manufacturing organization (CDMO) and JSR Life Sciences affiliate company. Lange will be responsible for setting KBI’s global vision, defining strategic priorities and ensuring KBI’s continuous focus on quality and innovation.
Sunnyvale, CA, ‐ October 31, 2019 ‐ JSR Life Sciences announced today that it has signed a technology licensing and joint development agreement with Dublin, Ireland-based GlycoSeLect, which provides recombinant prokaryotic lectins (RPLs) that enable the selective isolation of glycosylated biomolecules. The agreement will focus on the development of a glyco-affinity ligand and capture resin.
PeptiDream and JSR Begin a Joint Development Program to Identify Peptides Applicable to Affinity Chromatography
TOKYO, JAPAN – September 20, 2019 - JSR Corporation and PeptiDream Inc. have agreed to begin a joint development program to identify peptides applicable to the affinity chromatography*1 process used in the purification of biopharmaceuticals such as antibody therapeutics.
Sunnyvale, CA – July 11, 2019 – JSR Life Sciences, LLC announced today that it has expanded its footprint and technical capabilities through the opening of its Applications Center of Excellence in Durham, NC. The new facility provides state-of-the-art laboratory and work space for JSR’s Separations Sciences Group (SSG) to focus on applications development, customer support and training.
Leuven, Belgium – May 17, 2018 – JSR Life Sciences (JLS) is pleased to announce that it has completed its capacity expansion for production of its Amsphere™ A3 protein-A chromatography resin in Leuven, Belgium. The new facility has been built to the highest quality standards using state of the art engineering and is adjacent to JSR’s existing European operations, JSR Micro NV.
JSR Life Sciences Agrees to Acquire Pioneering Cell Line Developer Selexis SA and Integrate Selexis with KBI Biopharma, Inc.
JSR Life Sciences, the life-sciences focused division of JSR Corporation, will offer industry partners best-in-class CDMO services by complementing its commercial subsidiary KBI Biopharma with Selexis SA Technologies